Edition:
United States

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

10.82USD
3:59pm EST
Change (% chg)

$-0.08 (-0.73%)
Prev Close
$10.90
Open
$10.93
Day's High
$11.52
Day's Low
$10.53
Volume
57,316
Avg. Vol
26,570
52-wk High
$13.91
52-wk Low
$6.24

Latest Key Developments (Source: Significant Developments)

AC Immune SA reports quarterly ‍loss per share CHF 0.15
Monday, 13 Nov 2017 06:52am EST 

Nov 13 (Reuters) - AC Immune SA ::AC Immune SA reports third quarter 2017 financial results and corporate update.AC Immune SA qtrly ‍loss per share CHF 0.15 .Says qtrly adjusted loss per share CHF ‍0.16​.  Full Article

AC Immune to get milestone payment for Alzheimer drug
Thursday, 2 Nov 2017 06:36am EDT 

Nov 2 (Reuters) - AC Immune Ltd :Says to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's disease ‍​.Says upon the dosing of the first patient in the phase 2 clinical trial, AC Immune becomes eligible to receive a milestone payment of CHF 14 million, which is expected to be paid in the fourth quarter of 2017‍​.Says this will be the third milestone payment under the 2012 strategic collaboration and licensing agreement with Genentech.  Full Article

AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease
Thursday, 2 Nov 2017 06:23am EDT 

Nov 2 (Reuters) - Ac Immune Ltd :AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's Disease.Ac Immune - ‍upon dosing of first patient in phase 2 trial of RO7105705​, co becomes eligible to get milestone payment of CHF 14 million, expected in Q4 2017.  Full Article

AC Immune completes recruitment for low-dose cohort in world's first clinical trial for Anti-Abeta Vaccine
Tuesday, 12 Sep 2017 06:05am EDT 

Sept 12 (Reuters) - Ac Immune Ltd :AC Immune completes recruitment for low-dose Cohort in world's first clinical trial for Anti-Abeta Vaccine targeting alzheimer's disease-like characteristics in individuals with down syndrome.  Full Article

AC Immune reports Q2 ‍loss per share CHF 0.22​
Wednesday, 9 Aug 2017 06:45am EDT 

Aug 9 (Reuters) - Ac Immune Ltd :AC Immune reports second quarter 2017 financial results.Q2 revenue chf 800,000.AC Immune Ltd qtrly ‍loss per share chf 0.22​.AC Immune Ltd qtrly adjusted ‍loss per share chf 0.14​.Q2 earnings per share view chf -0.16 -- Thomson Reuters I/B/E/S.AC Immune Ltd qtrly revenues chf 800,000 versus chf 19.9 mln‍​.  Full Article

AC Immune SA reports qtrly loss per share CHF 0.17
Thursday, 11 May 2017 06:14am EDT 

May 11 (Reuters) - AC Immune Ltd : :AC Immune SA reports first quarter 2017 financial results.Qtrly loss per share CHF 0.17.Qtrly total revenues CHF 2.0 million versus. CHF 0.5 million.  Full Article

AC Immune generated revenue of chf 23.2 mln in twelve months ended Dec. 31, vs chf 39.1 mln
Friday, 17 Mar 2017 06:37am EDT 

Ac Immune Ltd : Ac immune reports full year 2016 financial results and research and development update . Ac immune ltd says generated revenues of chf 23.2 million in twelve months ended december 31, 2016, compared to chf 39.1 million in same period 2015 .Ac immune - for twelve months ended dec 31, 2016, had a net loss of chf 7.1 million compared with a profit of chf 20.3 million in twelve months period ended dec 31, 2015.  Full Article

AC Immune partner Genentech to start second Phase 3 clinical trial for Alzheimer's therapy Crenezumab
Tuesday, 28 Feb 2017 02:02am EST 

Ac Immune Ltd : Ac immune partner genentech to start second phase 3 clinical trial for alzheimer's therapy crenezumab .Ac immune will not receive any milestone payments for start of this second phase 3 trial.  Full Article

AC Immune shares open at $14.11 in debut, above IPO price of $11 per share
Friday, 23 Sep 2016 10:00am EDT 

: AC Immune shares open at $14.11 in debut, above IPO price of $11.0 per share Further company coverage: [ACIU.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-AC Immune SA reports quarterly ‍loss per share CHF 0.15

* AC Immune SA reports third quarter 2017 financial results and corporate update